NCT01659047View on ClinicalTrials.gov

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2015

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

GS-1101

150 mg taken twice daily by mouth

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY